 (NYSE:VEEV) today introduced its first application specifically built for clinical research centers, 

. The new solution will help sites more effectively manage regulatory documentation and trial information to speed clinical research. Now clinical research centers can reduce the administrative burden of executing studies by streamlining document and trial processes for site qualification, study activation, and investigator site file management. 

	“We’re pleased to partner with Veeva and have the opportunity to leverage an innovative solution that’s designed for how sites work,” said Dr. Jeff Kingsley, founder and CEO, IACT Health. “Veeva Vault SiteDocs gives greater visibility into regulatory document status and makes it easier for the clinical research community to conduct high-quality, compliant clinical trials.”

	Veeva Vault SiteDocs provides sites a single application for managing trial documents and processes to speed study activation. With continuous visibility into document quality, completeness, and accuracy, Vault SiteDocs gives clinical research centers a full view into study progress for improved compliance and inspection-readiness.

	“We’re honored to support the important work of clinical research centers and partner with organizations such as IACT Health and Penn Medicine,” said Jennifer Goldsmith, senior vice president of Veeva Vault. “Veeva Vault SiteDocs aims to simplify study execution so research staff can focus on the science and accelerate their research efforts.”

	Veeva Vault SiteDocs is available today for clinical research centers. Join Veeva at the upcoming 2018 Global Site Solutions Summit, Oct. 12-14, to learn more and see a demonstration of Veeva Vault SiteDocs in booth #501.

	Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit 

	This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

 
	Roger Villareal
	Veeva Systems
	925-264-8885
	

 
	
	Lisa Barbadora
	Veeva Systems
	610-420-3413
	